Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience

BACKGROUND: The efficacy of anti-programmed cell death (PD)-1 monotherapy in advanced hepatocellular carcinoma (aHCC) is limited, and combination therapy with lenvatinib and pembrolizumab has shown promising results. However, comparative studies between immune monotherapies and combination therapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qingyan, Li, Rong, Li, Lingling, Wang, Gaokun, Ji, Shiyu, Zheng, Xuan, Jia, Xiaodong, Tao, Haitao, Hu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599113/
https://www.ncbi.nlm.nih.gov/pubmed/37885459
http://dx.doi.org/10.1177/17588359231206274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599113/
https://www.ncbi.nlm.nih.gov/pubmed/37885459
http://dx.doi.org/10.1177/17588359231206274

Ejemplares similares